BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 11, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» IBI-3001, potentially first-in-class B7-H3/EGFR bsADC with broad anticancer efficacy and excellent in vivo safety
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
IBI-3001, potentially first-in-class B7-H3/EGFR bsADC with broad anticancer efficacy and excellent in vivo safety
April 9, 2024
No Comments
At the AACR meeting, Innovent Biologics Inc. discussed the discovery and preclinical evaluation of a B7-H3/EGFR bispecific antibody-drug conjugate (bsADC).
BioWorld Science
Conferences
American Association for Cancer Research
Cancer
Antibody-drug conjugate
Immuno-oncology
